HC Wainwright Has Strong Estimate for EWTX FY2026 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Equities research analysts at HC Wainwright lifted their FY2026 earnings estimates for Edgewise Therapeutics in a report issued on Thursday, November 5th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will post earnings of $9.29 per share for the year, up from their previous estimate of ($2.07). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is $5.43 per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q4 2026 earnings at ($0.47) EPS and FY2027 earnings at ($2.22) EPS.

Several other analysts have also commented on EWTX. JPMorgan Chase & Co. lifted their price objective on shares of Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Wedbush reduced their target price on shares of Edgewise Therapeutics from $53.00 to $51.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. William Blair started coverage on shares of Edgewise Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating for the company. The Goldman Sachs Group lifted their price target on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Finally, Raymond James Financial reaffirmed an “underperform” rating and issued a $85.00 price target on shares of Edgewise Therapeutics in a report on Thursday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.83.

Edgewise Therapeutics Stock Performance

EWTX opened at $48.74 on Monday. Edgewise Therapeutics has a fifty-two week low of $16.98 and a fifty-two week high of $48.78. The firm has a 50-day moving average of $40.97 and a 200 day moving average of $36.64. The firm has a market cap of $5.29 billion, a P/E ratio of 5.95 and a beta of 0.39.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $9.65 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $10.18.

Institutional Trading of Edgewise Therapeutics

Institutional investors have recently modified their holdings of the company. Parallel Advisors LLC raised its position in Edgewise Therapeutics by 64.9% in the first quarter. Parallel Advisors LLC now owns 1,032 shares of the company’s stock worth $33,000 after acquiring an additional 406 shares during the period. GAMMA Investing LLC grew its position in shares of Edgewise Therapeutics by 26.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,666 shares of the company’s stock valued at $108,000 after acquiring an additional 559 shares during the period. AlphaCentric Advisors LLC grew its position in shares of Edgewise Therapeutics by 4.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 16,572 shares of the company’s stock valued at $673,000 after acquiring an additional 732 shares during the period. KBC Group NV purchased a new stake in shares of Edgewise Therapeutics during the 1st quarter worth approximately $49,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Edgewise Therapeutics by 10.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,216 shares of the company’s stock worth $792,000 after purchasing an additional 1,843 shares during the last quarter.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 6,522 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.85, for a total value of $285,989.70. Following the completion of the sale, the chief marketing officer owned 11,544 shares in the company, valued at approximately $506,204.40. This represents a 36.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Kevin Koch sold 17,971 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $43.68, for a total transaction of $784,973.28. Following the transaction, the chief executive officer owned 52,488 shares in the company, valued at $2,292,675.84. The trade was a 25.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 38,329 shares of company stock valued at $1,675,529. Insiders own 21.30% of the company’s stock.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions.

Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.